Solid tumor oncology & cancer screening — Common solid tumors, staging, treatment principles, and screening.

Historical Context & Motivation

The understanding of solid tumor oncology has evolved dramatically over the past two centuries, transforming cancer from a uniformly fatal diagnosis to a disease in which early detection and targeted therapy can yield cure or long-term remission. Before the advent of modern surgical technique, cancers were often diagnosed only at advanced stages, and radical excision offered the sole therapeutic modality. The recognition that tumors follow predictable patterns of local growth, lymphatic spread, and distant metastasis laid the intellectual groundwork for formal staging systems and multimodal treatment strategies. Equally transformative was the realization that detecting malignancies before symptoms emerge—through population-level screening—could reduce cancer-specific mortality. Today, oncology integrates surgery, radiation, chemotherapy, immunotherapy, and precision medicine into individualized treatment plans, while evidence-based screening guidelines shape public health policy worldwide.

These milestones raise the central clinical questions that define modern oncology: How do we classify and stage solid tumors to guide prognosis and therapy? Which treatment modalities apply to which clinical scenarios? And which asymptomatic populations benefit from screening—and which are harmed by it? Answering these questions is essential to the clinical reasoning expected on USMLE Step 2 CK and in day-to-day patient care.

Core Principles of Solid Tumor Oncology

Solid tumors are neoplasms arising from epithelial, mesenchymal, or neuroectodermal tissue—as distinguished from hematologic malignancies originating in blood-forming cells. The core principles governing their clinical management can be distilled into several foundational concepts that inform every aspect of diagnosis, staging, and therapy.

TNM Staging & Treatment Algorithm — Visual Overview

As depicted in the diagram above, the clinical management pathway begins with accurate determination of the T, N, and M descriptors using imaging (CT, MRI, PET) and pathologic assessment. These descriptors are synthesized into an AJCC stage group that determines whether treatment intent is curative or palliative. Early-stage disease (stages I–II) generally permits definitive surgical resection, sometimes followed by adjuvant chemotherapy or radiation to eliminate micrometastatic disease. Locally advanced tumors (stage III) often benefit from neoadjuvant (pre-operative) systemic therapy to downstage the tumor, followed by surgery and adjuvant therapy. Stage IV metastatic disease is typically treated with systemic therapy—chemotherapy, targeted agents, immunotherapy, or hormonal therapy—selected based on tumor histology, molecular profile, and patient performance status.

Treatment Principles & Mechanisms

Solid tumor treatment rests on the integration of local therapies (surgery and radiation) with systemic therapies (chemotherapy, targeted therapy, immunotherapy, hormonal therapy). Understanding the mechanism and clinical rationale for each modality is essential for selecting the right combination and sequence.

Surgical Principles

Surgery remains the only modality that can independently cure most solid tumors when disease is localized. The goal is complete resection with negative margins (R0 resection). Sentinel lymph node biopsy—pioneered in melanoma and breast cancer—allows selective nodal sampling, avoiding the morbidity of complete lymph node dissection when sentinel nodes are negative. The concept of margin status is critical: R0 indicates microscopically negative margins, R1 indicates microscopically positive margins, and R2 indicates grossly positive (macroscopic residual) disease. Only R0 resections are considered curative.

Radiation Therapy

Radiation therapy uses ionizing radiation to induce DNA double-strand breaks in tumor cells, leading to mitotic catastrophe and apoptosis. It can be delivered as external beam radiation therapy (EBRT) or brachytherapy (internal radiation seeds). Radiation is used as definitive therapy (e.g., early cervical cancer, head and neck squamous cell carcinoma), adjuvant therapy after surgery (e.g., breast-conserving therapy), or palliative therapy for symptomatic metastases (e.g., bone pain, brain metastases). The therapeutic ratio describes the balance between tumor cell kill and normal tissue toxicity—fractionation (dividing the total dose into daily fractions) exploits the superior DNA repair capacity of normal cells compared to tumor cells.

Systemic Therapy Mechanisms

High-Yield Common Solid Tumors

USMLE Step 2 CK emphasizes recognition of common presentations, risk factors, diagnostic workup, and first-line treatment for the most prevalent solid tumors. The following tumor-specific summaries focus on the details most frequently tested.

Breast Cancer — Subtypes and Treatment

Breast cancer is the most common malignancy in women and is subclassified by receptor status into clinically actionable subtypes. ER/PR-positive tumors (luminal A and luminal B) are the most common and are treated with endocrine therapy—tamoxifen in premenopausal women and aromatase inhibitors (letrozole, anastrozole) in postmenopausal women—often for 5 to 10 years. HER2-positive tumors are treated with anti-HER2 agents including trastuzumab, pertuzumab, and the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine). Triple-negative breast cancer (TNBC) lacks ER, PR, and HER2 expression, is more aggressive, and is treated primarily with cytotoxic chemotherapy. Emerging data support the use of pembrolizumab plus chemotherapy in PD-L1-positive TNBC and PARP inhibitors (olaparib, talazoparib) in BRCA-mutated disease.

Lung Cancer — NSCLC vs. SCLC

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers and includes adenocarcinoma (most common, peripheral location), squamous cell carcinoma (central, cavitating), and large cell carcinoma. All NSCLC patients should undergo molecular testing for actionable driver mutations: EGFR mutations (treated with osimertinib), ALK rearrangements (alectinib), ROS1 fusions (crizotinib), and BRAF V600E (dabrafenib/trametinib). PD-L1 expression guides immunotherapy selection. Small cell lung cancer (SCLC) is staged as limited or extensive and is highly chemosensitive initially but relapses aggressively; first-line treatment is etoposide-platinum, with atezolizumab added in extensive-stage disease.

Colorectal Cancer — The Adenoma–Carcinoma Sequence

Colorectal cancer (CRC) classically follows the adenoma-to-carcinoma sequence, driven by stepwise accumulation of mutations (APC → KRAS → TP53). Hereditary syndromes include Lynch syndrome (hereditary nonpolyposis colorectal cancer, caused by mismatch repair gene mutations—MLH1, MSH2, MSH6, PMS2) and familial adenomatous polyposis (FAP) (germline APC mutation, hundreds of polyps, near 100% cancer risk without prophylactic colectomy). Stage III CRC is treated with surgical resection plus adjuvant FOLFOX (5-FU, leucovorin, oxaliplatin). In metastatic CRC, RAS/BRAF mutation status and mismatch repair status guide therapy—anti-EGFR antibodies (cetuximab, panitumumab) are used only in RAS wild-type tumors, and pembrolizumab is first-line for MSI-H/dMMR metastatic CRC.

Worked Example — Clinical Vignette

The following clinical vignette demonstrates the systematic approach to a solid tumor question on the USMLE Step 2 CK, integrating presentation, staging, molecular subtyping, and treatment selection.

Cancer Screening Guidelines

Cancer screening is one of the most frequently tested topics on the USMLE Step 2 CK. The key principle is that screening should only be recommended when there is high-quality evidence that it reduces cancer-specific mortality in the target population, and that the benefits of screening outweigh the harms (including false positives, overdiagnosis, anxiety, and complications from diagnostic procedures). The U.S. Preventive Services Task Force (USPSTF) assigns evidence grades from A (strongly recommended) to D (recommended against), with I indicating insufficient evidence.

Precision Oncology & Emerging Paradigms

The traditional paradigm of treating cancer based solely on histology and anatomic site is being supplanted by precision oncology—a tissue-agnostic, biomarker-driven approach. The FDA's approval of pembrolizumab for any MSI-H/dMMR solid tumor, regardless of primary site, marked a watershed moment: the first drug approved based entirely on a molecular biomarker rather than tumor origin. Similarly, larotrectinib and entrectinib are approved for any NTRK fusion-positive cancer. This paradigm shift necessitates routine molecular profiling of advanced solid tumors.

Additional concepts increasingly relevant to clinical practice and likely to appear on future examinations include immune-related adverse events (irAEs) from checkpoint inhibitors—autoimmune colitis, pneumonitis, hepatitis, thyroiditis, and hypophysitis—which require prompt recognition and management with corticosteroids. Tumor mutational burden (TMB) has emerged as a tissue-agnostic biomarker for immunotherapy response. Furthermore, liquid biopsy—analyzing circulating tumor DNA in peripheral blood—enables noninvasive genotyping, minimal residual disease detection, and resistance mechanism identification without repeat tissue biopsy.

Practice Problems

Solid Tumor Oncology & Cancer Screening — Summary